The TELO2 immunostain score was significant higher in high-grade (WHO grade III, and IV) gliomas than in low-grade (WHO grade I, and II) gliomas or normal brain (P = 2.19×10−3, 7.53×10−6, respectively). This evidence concerns the gene TELO2 and glioma.